12:00 AM
 | 
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Efinaconazole regulatory update

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX, Mississauga, Ontario) said it received a complete response letter from FDA for an NDA for efinaconazole to treat onychomycosis. The company said FDA's questions pertain to CMC-related areas of the container closure apparatus and that the agency...

Read the full 205 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >